In 323 asymptomatic patients undergoing EGD surveillance, two patients (0.6%), both with an MSH2 pathogenic variant, were found to have gastric cancer—one type 3 gastric neuroendocrine tumor and one gastric adenocarcinoma identified as a solitary ulcerated mass in the proximal stomach [31]. This evidence concerns the gene MSH2 and gastric neuroendocrine tumor, well differentiated, low or intermediate grade.